Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS – Research Report), Merck & Company (MRK – Research Report) and Integra Lifesciences (IART – Research Report).
Ionis Pharmaceuticals (IONS)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $88.00. The company’s shares closed last Wednesday at $44.37.
According to TipRanks.com, Zhu is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Ionis Pharmaceuticals is a Moderate Buy with an average price target of $56.45.
See today’s best-performing stocks on TipRanks >>
Merck & Company (MRK)
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on Merck & Company, with a price target of $130.00. The company’s shares closed last Wednesday at $103.63.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $124.79 average price target, a 20.7% upside from current levels. In a report issued on October 20, UBS also upgraded the stock to Buy with a $122.00 price target.
Integra Lifesciences (IART)
Bank of America Securities analyst Craig Bijou reiterated a Sell rating on Integra Lifesciences yesterday and set a price target of $40.00. The company’s shares closed last Wednesday at $35.35.
According to TipRanks.com, Bijou is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Integra Lifesciences with a $45.38 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IONS:
- Ionis Pharmaceuticals upgraded to Neutral from Underperform at BofA
- Biotech Alert: Searches spiking for these stocks today
- Ionis announces new results from analysis of exploratory cardiac endpoints
- ‘Load Up,’ Says Raymond James About These 2 ‘Strong Buy’ Stocks
- Ionis Pharmaceuticals to hold a R&D Day
